Namju Kim Shin
Adult Health · la Palma, CANPI 1326377292
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 350 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 350 payments — averaging $23.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$982
- Boehringer Ingelheim$726
- Lilly USA, LLC$682
- AbbVie$569
- Amgen$481
- plus $4K from 30 others
What the payments were for
- Food & beverage$8,051100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $1,011 |
| Novo Nordisk | 56 | $982 |
| Boehringer Ingelheim | 28 | $726 |
| Lilly USA, LLC | 28 | $682 |
| AbbVie | 30 | $569 |
| Amgen | 19 | $481 |
| Nestle Healthcare Nutrition Inc. | 18 | $396 |
| Aimmune Therapeutics, Inc. | 16 | $348 |
| Dexcom, Inc. | 12 | $346 |
| Bayer | 14 | $316 |
| Pfizer | 6 | $243 |
| Astellas Pharma US Inc | 11 | $230 |
| Ironwood Pharmaceuticals, Inc | 8 | $191 |
| Abbott | 8 | $190 |
| Johnson & Johnson | 8 | $170 |
| Esperion Therapeutics, Inc. | 7 | $166 |
| Novartis | 5 | $124 |
| Amarin Pharma, Inc. | 5 | $111 |
| Lundbeck LLC | 5 | $92 |
| Otsuka America Pharmaceutical, Inc. | 4 | $90 |
| Scilex Pharmaceuticals Inc. | 4 | $81 |
| Vivus LLC | 4 | $74 |
| Scpharmaceuticals Inc. | 3 | $66 |
| Alnylam Pharmaceuticals Inc. | 2 | $59 |
| Vanda Pharmaceuticals Inc. | 2 | $53 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $49 |
| Merck | 1 | $26 |
| Analog Devices Inc. | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Exact Sciences | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Cleerly, Inc. | 1 | $19 |
| Biogen | 1 | $18 |
| Edwards Lifesciences | 1 | $18 |
| Almatica Pharma LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,051 in reported general payments places this provider in the 95th percentile of 785 adult health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 1,011 | $400,167 |
| ZenpepLipase/Protease/Amylase | 257 | $357,317 |
| CreonLipase/Protease/Amylase | 299 | $321,163 |
| JardianceEmpagliflozin | 288 | $208,807 |
| FarxigaDapagliflozin Propanediol | 271 | $192,504 |
| JanuviaSitagliptin Phosphate | 216 | $147,812 |
| LinzessLinaclotide | 198 | $122,738 |
| OzempicSemaglutide | 91 | $108,236 |
| TradjentaLinagliptin | 197 | $106,919 |
| EliquisApixaban | 149 | $94,052 |
| ProliaDenosumab | 49 | $81,300 |
| ZtlidoLidocaine | 96 | $56,452 |
| Icosapent Ethyl | 271 | $56,340 |
| MyrbetriqMirabegron | 103 | $53,204 |
| XareltoRivaroxaban | 71 | $52,284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Restasis | $569 | $454,624516 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Trijardy Xr, Synjardy | $726 | $361,847537 claims |
| Aimmune Therapeutics, Inc.Zenpep | $348 | $357,317257 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,011 | $229,940329 claims |
| MerckJanuvia, Janumet, Janumet Xr | $26 | $169,151256 claims |
| Novo NordiskOzempic | $982 | $108,23691 claims |
| PfizerEliquis | $243 | $94,052149 claims |
| AmgenProlia | $481 | $81,30049 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $81 | $56,45296 claims |
| Astellas Pharma US IncMyrbetriq | $230 | $53,204103 claims |
| Johnson & JohnsonXarelto | $170 | $52,28471 claims |
| Lilly USA, LLCTrulicity | $682 | $47,80143 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 785 adult health providers in California.
Other adult health in la Palma
- Karolina FaysmanLos Angeles$1.1M
- Linda BuckLos Angeles$170K
- Naomi PesynaAnaheim$141K
- Stacy GrissenEncinitas$82K
- Kimberly PodsadaSan Diego$78K
- Brenda PatrickSan Leandro$68K
- Brittany PolizziEncinitas$35K
- Nancy NicolosiLaguna Woods$31K
- Michele WestendorfNewport Beach$30K
- Lisa HinemanLos Angeles$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.